Visiongate, Inc.

Bothell, WA

UEI
EMJ7LWRRNED7
CAGE
3YYR6
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
22121 17th Ave SE e 114, Bothell, WA 98021, USA
Founded
2001
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Sbir topic 195, virtual microscopy for the early detection of cancer HHSN261200433010C National Cancer Institute (NIH) $99,979

Grant awards

Award Agency Obligated Awarded
Development of high-throughput commercially viable cell-CT instrument with init RC3GM093818 National Institutes of Health $2,621,703
Development of a vascularized in-vitro model of the tumor microenvironment R43CA144469 National Institutes of Health $188,226
Development of an organotypic in-vitro model of the blood-brain barrier R43NS070440 National Institutes of Health $190,632

SBA capabilities narrative

From the vendor's SBA profile

The foundation for our diagnostics capability is our proprietary Cell-CT 3-Dimensional Cell Imaging and Analysis platform that we believe will transform the ability to image and detect abnormal cells. The Cell-CT platform, using a process called optical computed tomography (Optical CT), produces isometric, sub-micron resolution 3D images of individual cells with the ability to morphologically recognize over 700 structural biomarkers of normal and abnormal cells. VisionGate is developing the Cell-CT platform to improve its ability to identify biosignatures that would classify cells to aid in abnormal cell detection and prediction of disease. The Cell-CT platform can process any liquid biopsy specimen. As such, it has the potential to detect a wide range of different cancers and cancer biosignatures. This could aid in identifying potential treatments using targeted pharmaceutical therapies.

Quick answers

Is Visiongate, Inc. registered in SAM.gov?

Yes. Visiongate, Inc.'s SAM.gov registration is active through March 25, 2027.

What is Visiongate, Inc.'s most recent federal award?

Visiongate, Inc.'s most recent federal grant award is Development of high-throughput commercially viable cell-CT instrument with init (RC3GM093818), from National Institutes of Health, on July 1, 2010.

On GovTribe

See Visiongate, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login